ArticleClinical, cosmetic and investigational dermatology2024
Impact of Herpes Zoster and Postherpetic Neuralgia on the Quality of Life in China: A Prospective Study.
Article in Clinical, cosmetic and investigational dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Current advances in the epidemiology, risk factors, prevention, management, and long-term outcomes of herpes zoster and post-herpetic neuralgia.Frontiers in microbiology · 2026Pooled it
- Clinical research on traditional Chinese medicine for Postherpetic neuralgia: an evidence map.Frontiers in neurology · 2025Pooled it
- Cost-effectiveness of herpes zoster vaccination in patients with rheumatoid arthritis.Rheumatology (Oxford, England) · 2026Article
- Postherpetic neuralgia risk prediction in hospitalised patients with herpes zoster based on MIMIC-IV.Medicine · 2026Article
- Targeting Neuroinflammation and Peripheral Nerve Dysfunction in Refractory Postherpetic Neuralgia: A Multimodal Injection Case Series.The American journal of case reports · 2026Article
- Disease burden and health-related quality of life among adults aged 50 years or older with herpes zoster in Huzhou, China.Frontiers in public health · 2026Article
- Venlafaxine for the Prevention of Postherpetic Neuralgia in Patients with Acute Herpes Zoster: Protocol for a Randomized Controlled Trial.Journal of pain research · 2026Article
- Comparative Efficacy of Pulsed Radiofrequency-Based and Related Interventions for Postherpetic Neuralgia: A Network Meta-Analysis of Randomized Controlled Trials.Journal of pain research · 2026Review
- Quality of life in people with herpes zoster: a cross-sectional study in China.Health and quality of life outcomes · 2025Article
- Development and validation of a machine learning model for predicting postherpetic neuralgia risk.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Herpes zoster (HZ) and postherpetic neuralgia (PHN) significantly affect patients' quality of life (QoL). Cultural differences may lead to different patient-reported outcomes across countries. The current study aims to evaluate the detrimental impact of HZ and PHN on QoL in China. Methods: This prospective study was conducted from January 2020 to April 2023. We used the Zoster Brief Pain Inventory (ZBPI) and 5-level EuroQol-5 Dimension (EQ-5D-5L) questionnaire to assess the QoL of HZ and PHN patients. Patients were required to complete the questionnaires at 15, 30, 60, and 90 days after the onset of the HZ rash. Additional questionnaires were administered at 120, 150, and 180 days for those who developed PHN within three months of the rash's onset. Results: A cohort of 633 patients with a median age of 63 years were included in the study. The mean delay from the appearance of the initial HZ rash to the first medical consultation was 5.1 ± 2.8 days. Approximately 30% of the HZ patients (189/633) went on to develop PHN. For patients with HZ who did not progress to PHN, the ZBPI worst pain score and impaired QoL had nearly resolved by day 90 post-rash onset. Conversely, there was no significant improvement in the ZBPI worst pain score and QoL for those with PHN, even by day 180 post-rash onset. Conclusion: Both HZ and PHN significantly impaired patients' QoL. However, the impairment caused by PHN was more severe in both intensity and duration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.